MANZANITA PHARMACEUTICALS, INC.
NerveLight, a near-infrared fluorescent nerve imaging agent comprised of a NIR dye conjugated to recombinant human Nerve Growth Factor (rhNGF) for intraoperative nerve visualization during radical pro
Follows are private to you and power your alerts
Updated · manzanitapharmaceuticals.com
- Sector
- Medtech
- Total capital
- $4.7M
- Federal grants
- $4.7M
- 4 awards · 2017–2025
- Rank in peer group#17 of 41
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 1
- 11 pending · first 2024
- Rank in peer group#13 of 41
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · Toxicology (IND-enabling) studies for a novel nerve imaging agent for prostate cancer$1.1M
- Federal grantHealth and Human S · Phase II · Toxicology (IND-enabling) studies for a novel nerve imaging agent for prostate cancer$906K
- Federal grantHealth and Human S · Phase II · Nonclinical development of Nervelight, an intra-operative peripheral nerve imaging agent$753K
- Federal grantHealth and Human S · Phase II · Nonclinical development of Nervelight, an intra-operative peripheral nerve imaging agent$2M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 41 peers
Line = medianMedtech · Molecule
- Federal grants#17 · top 41%
- Granted patents#13 · top 32%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 1 granted of 12- PendingMethods For Using Neurotrophin Receptor Binding Conjugate Compositions In The Treatment Of A Neurological ConditionUSPTOApplication 18039126
- GrantedConjugates For Delivering An Anti-cancer Agent To Nerve Cells, Methods Of Use And Methods Of Making ThereofUSPTOUS 11,897,928
- PendingNeurotrophin Receptor Binding Conjugate Compositions, Methods Of Use And Methods Of Making ThereofUSPTOApplication 17769693
Show all 12 patent records
- Methods For Using Neurotrophin Receptor Binding Conjugate Compositions In The Treatment Of A Neurological ConditionSep 5, 2024 · Application 18039126Pending
- Conjugates For Delivering An Anti-cancer Agent To Nerve Cells, Methods Of Use And Methods Of Making ThereofFeb 13, 2024 · US 11,897,928Granted
- Neurotrophin Receptor Binding Conjugate Compositions, Methods Of Use And Methods Of Making ThereofDec 1, 2022 · Application 17769693Pending
- Methods For Using Neurotrophin Receptor Binding Conjugate Compositions In The Treatment Of NeuroinflammationApplication 63119471Pending
- Neurotrophin Receptor Binding Conjugate Compositions, Methods Of Use And Methods Of Making ThereofApplication PCTUS2020056866Pending
- Conjugate Compounds For Intraocular Delivery And Methods Of Use ThereofApplication 62976725Pending
- Dual Color Tissue Imaging Compositions And Methods Of Use ThereofApplication 62967828Pending
- Neurotrophin Receptor Binding Conjugate Compositions For Delivering An Active Agent To Nerve Cells, Methods Of Use And Methods Of Making ThereofApplication 62924965Pending
- Conjugates For Delivering An Anti-cancer Agent To Nerve Cells, Methods Of Use And Methods Of Making ThereofApplication PCTUS2019042253Pending
- Conjugates For Delivering An Anti-cancer Agent To Nerve Cells, Methods Of Use And Methods Of Making ThereofApplication 62700131Pending
- Methods For Using Neurotrophin Receptor Binding Conjugate Compositions In The Treatment Of A Neurological ConditionApplication PCTUS2021061167Pending
- Methods For Using Neurotrophin Receptor Binding Conjugate Compositions In The Treatment Of A Neurological ConditionApplication 63161419Pending
Related companies, and why
- AMPA INC.Similar federal contract value in Medtech · null in contracts
- Morgan and Mendel Genomics, Inc.Similar federal contract value in Medtech · null in contracts
- Pinnacle Technology, Inc.Similar federal contract value in Medtech · null in contracts
- GOODLIFE INVENTORS LLCSimilar federal contract value in Medtech · null in contracts
- ALAN PENN AND ASSOCIATES, INC.Similar federal contract value in Medtech · null in contracts
- NEXTRAST, INCSimilar federal contract value in Medtech · null in contracts
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .